Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study

Kenji Morimoto, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu, Yuta Okazaki, Taishi Harada, Takayo Ota, Ken Masubuchi, Koji Mikami, Tae Hata, Shoki Matsumoto, Ryoichi Honda, Koji Date, Yusuke Chihara, Koichi Takayama

Open source

DOI: 10.1016/j.lungcan.2025.108447
Published: 2025-03
Container: Lung Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.lungcan.2025.108447,
  title = {Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study},
  author = {Kenji Morimoto and Tadaaki Yamada and Naoki Furuya and Hisashi Tanaka and Akihiro Yoshimura and Tomohiro Oba and Makoto Hibino and Takahito Fukuda and Yasuhiro Goto and Akira Nakao and Shinsuke Ogusu and Yuta Okazaki and Taishi Harada and Takayo Ota and Ken Masubuchi and Koji Mikami and Tae Hata and Shoki Matsumoto and Ryoichi Honda and Koji Date and Yusuke Chihara and Koichi Takayama},
  year = {2025},
  journal = {Lung Cancer},
  doi = {10.1016/j.lungcan.2025.108447},
  url = {https://doi.org/10.1016/j.lungcan.2025.108447}
}

RIS

TY  - JOUR
TI  - Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study
AU  - Kenji Morimoto
AU  - Tadaaki Yamada
AU  - Naoki Furuya
AU  - Hisashi Tanaka
AU  - Akihiro Yoshimura
AU  - Tomohiro Oba
AU  - Makoto Hibino
AU  - Takahito Fukuda
AU  - Yasuhiro Goto
AU  - Akira Nakao
AU  - Shinsuke Ogusu
AU  - Yuta Okazaki
AU  - Taishi Harada
AU  - Takayo Ota
AU  - Ken Masubuchi
AU  - Koji Mikami
AU  - Tae Hata
AU  - Shoki Matsumoto
AU  - Ryoichi Honda
AU  - Koji Date
AU  - Yusuke Chihara
AU  - Koichi Takayama
PY  - 2025
JO  - Lung Cancer
DO  - 10.1016/j.lungcan.2025.108447
UR  - https://doi.org/10.1016/j.lungcan.2025.108447
ER  -

APA

Morimoto, K., Yamada, T., Furuya, N., Tanaka, H., Yoshimura, A., Oba, T., Hibino, M., Fukuda, T., Goto, Y., Nakao, A., Ogusu, S., Okazaki, Y., Harada, T., Ota, T., Masubuchi, K., Mikami, K., Hata, T., Matsumoto, S., Honda, R., Date, K., Chihara, Y., & Takayama, K. (2025). Exploration of clinical Biomarkers for guiding treatment selection between chemotherapy and combination therapy with Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR-Mutant NSCLC patients after EGFR-TKI Therapy: The SPIRAL-STEP study. Lung Cancer. https://doi.org/10.1016/j.lungcan.2025.108447

Source records

crossref · retrieved 2026-09-27T01:12:33.764Z